| 摘要 |
The invention is directed to the treatment of lung cancer, preferably non-small cell lung cancer (NSCLC) by means of a combination therapy comprising chemo- radiotherapy and vaccination with muc-1 lipopeptides, preferably tecemotide (L-BLP- 25). The invention relates, above all, to specific biomarkers which are overexpressed and released into the peripheral blood of patients suffering from lung cancer, preferably NSLC, who respond to the vaccination treatment with said drug in combination with chemo-radiotherapy, preferably concurrent chemo-radiotherapy prior to vaccination, compared to respective patients who do not respond or do weakly respond to said treatment. |
